Trials / Unknown
UnknownNCT01255046
Study of STA-1 as an Add-on Treatment to Donepezil
A Phase II Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of STA-1 as an Add-on Treatment to Donepezil in Patients With Mild to Moderate Alzheimer's Disease
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 136 (estimated)
- Sponsor
- Sinphar Pharmaceutical Co., Ltd · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy and safety of STA-1 vs placebo as an add-on treatment to donepezil in patients with mild to moderate Alzheimer's Disease (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Donepezil, | 10mg/tab, 1 tab/day for 72 weeks |
| DRUG | STA-1 | 300mg/tab, 2 tab/tid for 72 weeks |
| DRUG | placebo | 2 tab/tid for 72 weeks |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2018-12-01
- First posted
- 2010-12-07
- Last updated
- 2014-08-20
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01255046. Inclusion in this directory is not an endorsement.